Where to find us
About UCB Ventures
- UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. We make long term investments in early stage companies in the US and Europe. Our portfolio reflects our investment strategy.
- We invest in start-ups developing novel therapeutic modalities, platforms/assets that address novel biology, or innovative digital solutions, in areas adjacent to or even beyond UCB's current therapeutic focus. We are seeking breakthrough innovations in next generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, RNA targeted therapeutics, and patient engagement solutions that significantly improve outcomes.
- We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed long term investors, working closely with entrepreneurs to bring out the best in our portfolio companies.
Syndesi Therapeutics announces the expansion of its management team with the appointment of Torsten Madsen, MD, PhD as Chief Medical Officer.
19 Dec 2019 — Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced Torsten Madsen MD, PhD has joined its management team as Chief Medical Officer.read more